Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Stereotaxis announces first successful cardiac ablation procedure with Vdrive robotic navigation system

Stereotaxis, Inc. announces the first successful cardiac ablation procedure with the Vdrive™ robotic navigation system as the company received CE Mark for this latest innovation.

11 Jan 2011

World's first drug eluting bioresorbable vascular scaffold receives CE Mark approval

Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.

10 Jan 2011

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

NovaDel Pharma Inc. today announced that it has received a $500,000 milestone payment from Akrimax Pharmaceuticals. The milestone payment was received in connection with the license and distribution agreement, dated October 27, 2009, between NovaDel Pharma Inc. and Mist Acquisition, LLC, an affiliate of Akrimax Pharmaceuticals.

7 Jan 2011

Stereotaxis extends strategic partnership to distribute magnetic ablation catheters

Stereotaxis, Inc. announced today that the Company and its existing strategic catheter partner have extended their exclusive worldwide agreement for the distribution of existing approved magnetic ablation catheters through the end of 2015.

6 Jan 2011

Deceptive food labels lead to increased risk of deadly diseases

Did you know that when you pick up a product promoted as trans fat free, you may still be ingesting a significant amount of this potentially harmful substance? An article by Case Western Reserve University School of Medicine student Eric Brandt, published in the January/February 2011 issue of the American Journal of Health Promotion, reveals that misleading labeling practices can result in medically significant intake of harmful trans fat, despite what you read on Food and Drug Administration (FDA) approved labels.

3 Jan 2011

InfraReDx to receive $862,000 as part of MLSC Tax Incentive Program

InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has been selected to receive an award of nearly $862,000 as part of the Massachusetts Life Sciences Center Tax Incentive Program. In conjunction with the award, InfraReDx has committed to create 32 new jobs during 2011.

24 Dec 2010

FDA approves Novartis' Amturnide for treatment of high blood pressure

Today Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure. Amturnide combines the only approved direct renin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ).

23 Dec 2010

Top ten advances in cardiovascular, stroke research in 2010

Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research recognized by the American Heart Association/American Stroke Association.

22 Dec 2010

Tryton initiates enrollment in Side Branch Stent System trial for coronary artery disease

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first patient has been enrolled in the pivotal trial to evaluate the Tryton Side Branch Stent System™ for the treatment of coronary artery disease.

20 Dec 2010

Stereotaxis closes $40 million credit facility

Stereotaxis, Inc. announced today that the Company has closed on its previously announced $40 million credit facility, which includes a $30 million revolving facility that matures on March 31, 2012 and a $10 million term loan that matures on December 31, 2013. The new facility was led by Silicon Valley Bank, and replaces the Company's previous facility that was scheduled to mature in March 2011.

20 Dec 2010

FFR-guided percutaneous coronary intervention provides cost-saving benefits

St. Jude Medical, Inc., a global medical device company, today announced the publication of results from an economic evaluation of the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial, which confirmed FFR-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease improves patient outcomes and offers cost-saving benefits to the U.S. healthcare system.

17 Dec 2010

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Viron Therapeutics Inc. today announced that the results of Viron's Phase 2a trial for VT-111 were published today in Circulation: Cardiovascular Interventions. In the study led by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, VT-111, also known as Serp-1, met both its primary and secondary endpoints of safety and biological activity in Acute Coronary Syndrome patients receiving coronary stents.

17 Dec 2010

Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

Zogenix, Inc. today announced that CONNECT, a regional San Diego nonprofit organization, selected SUMAVEL® DosePro™ (sumatriptan injection) Needle-free Delivery System as a 2010 Most Innovative Product (MIP) winner at the MIP Awards Luncheon on December 10, 2010.

13 Dec 2010

U-M's participation in Medicare Physician Group Practice Demonstration Project helps save over $15 million

Medicare patients with a host of physical problems are getting better care at the University of Michigan Health System, and U-M staff have saved more than $15 million on the cost of that care over four years.

13 Dec 2010

Chinese study examines association between alcohol intake, CAD

Among a large number of Chinese men presenting with chest pain or EKG changes, sequential subjects undergoing cardiac angiography were evaluated for obstructive coronary artery disease lesions according to their reported recent alcohol intake. The study population consisted of 1,476 consecutive men 36 to 84 years of age; participants were categorized as nondrinkers, light drinkers, moderate drinkers, or heavy drinkers.

10 Dec 2010

Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure

Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.

9 Dec 2010

Detection of blood biomarker cTnT associated with structural heart disease

With the use of a highly sensitive test, detection of the blood biomarker cardiac troponin T, a cardiac-specific protein, is associated with structural heart disease and an increased risk of all-cause death, according to a study in the December 8 issue of JAMA.

8 Dec 2010

New sensitive blood test could determine unrecognized heart disease

A more sensitive version of a blood test typically used to confirm that someone is having a heart attack could indicate whether a seemingly healthy, middle-aged person has unrecognized heart disease and an increased risk of dying, UT Southwestern Medical Center researchers have found.

7 Dec 2010

Sheathless transradial intervention highly successful in treating complex lesions

Cardiologists from the Mayo Clinic performed sheathless transradial percutaneous coronary intervention (PCI) to remedy complex lesions, achieving a 90% success rate with no radial complications. Standard guiding catheters were used during the procedure. Details of this novel approach—overcoming the last hurdle to greater adoption of transradial PCI in the U.S.—are published in the December issue of Catheterization and Cardiovascular Intervention, the official journal of The Society for Cardiovascular Angiography and Interventions.

7 Dec 2010

Stereotaxis awarded VA Federal Supply Schedule Contract for Niobe Remote Magnetic Navigation System

Stereotaxis, Inc. announced that the United States Department of Veteran Affairs awarded Stereotaxis a Federal Supply Schedule Contract for its Niobe® Remote Magnetic Navigation System, related service agreement, and disposable products. This contract, effective December 15, 2010, is for five years, with a five year renewal option.

7 Dec 2010

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Stereotaxis announces first successful cardiac ablation procedure with Vdrive robotic navigation system

World's first drug eluting bioresorbable vascular scaffold receives CE Mark approval

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

Stereotaxis extends strategic partnership to distribute magnetic ablation catheters

Deceptive food labels lead to increased risk of deadly diseases

InfraReDx to receive $862,000 as part of MLSC Tax Incentive Program

FDA approves Novartis' Amturnide for treatment of high blood pressure

Top ten advances in cardiovascular, stroke research in 2010

Tryton initiates enrollment in Side Branch Stent System trial for coronary artery disease

Stereotaxis closes $40 million credit facility

FFR-guided percutaneous coronary intervention provides cost-saving benefits

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

U-M's participation in Medicare Physician Group Practice Demonstration Project helps save over $15 million

Chinese study examines association between alcohol intake, CAD

Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure

Detection of blood biomarker cTnT associated with structural heart disease

New sensitive blood test could determine unrecognized heart disease

Sheathless transradial intervention highly successful in treating complex lesions

Stereotaxis awarded VA Federal Supply Schedule Contract for Niobe Remote Magnetic Navigation System

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in